Skip to main content
  • Home
  • Dana-Farber Brigham Cancer Center
Institutional profile

Dana-Farber Brigham Cancer Center

Dana-Farber Brigham Cancer Center is a major oncology Center of Excellence combining the cancer expertise of Dana-Farber Cancer Institute with the clinical and hospital infrastructure of Mass General Brigham. The platform provides specialized cancer care across medical oncology, surgical oncology, radiation oncology, hematologic malignancies, immunotherapy, precision medicine, and clinical trials.

  • Highest 2026 tier: Tier II
  • Centers of Excellence
  • 1 ranking category

Overview

Dana-Farber Brigham Cancer Center is a major oncology Center of Excellence combining the cancer expertise of Dana-Farber Cancer Institute with the clinical and hospital infrastructure of Mass General Brigham. The platform provides specialized cancer care across medical oncology, surgical oncology, radiation oncology, hematologic malignancies, immunotherapy, precision medicine, and clinical trials.

Its strength lies in the integration of academic research and advanced clinical care. Cancer care increasingly depends on molecular diagnostics, targeted therapies, cell therapy, multidisciplinary tumor boards, and access to investigational treatments. Dana-Farber Brigham’s model is structured around these complex oncology needs.

Dana-Farber Brigham Cancer Center is included in 1 2026 ranking category. Its highest classification is Tier II. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.

Firm facts

Public identityDana-Farber Brigham Cancer Center
Institutional scopeClinical collaboration of Dana-Farber Cancer Institute and Brigham and Women’s Hospital
Institution typeCenters of Excellence institution
HeadquartersBoston, United States
Primary focusCenters of Excellence
Highest 2026 ranking tierTier II

Principal activities

Its strength lies in the integration of academic research and advanced clinical care. Cancer care increasingly depends on molecular diagnostics, targeted therapies, cell therapy, multidisciplinary tumor boards, and access to investigational treatments. Dana-Farber Brigham’s model is structured around these complex oncology needs.

Core capability

Centers of Excellence

Client relevance

Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.

Execution and verification

Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.

Sector and mandate coverage

Primary category

Centers of Excellence

Institutional context

Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.

Market position

Dana-Farber Brigham’s focused oncology identity, research depth, academic affiliations, and specialist clinical platform support its inclusion among established Centers of Excellence.

Dana-Farber Brigham Cancer Center is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier II.

Competitive context

The relevant peer set varies by category, geography, client segment and mandate. Dana-Farber Brigham Cancer Center should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.

Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.

Leadership and governance

Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.

Corporate and public information

The public-facing organization is identified here as Dana-Farber Brigham Cancer Center. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.

Corporate and disclosure information
OrganizationDana-Farber Brigham Cancer Center
HeadquartersBoston, United States
Verification noteConfirm legal entity, licenses, offices and engagement terms directly before appointment or use.

Additional published ranking appearances

These entries retain the edition, classification and assessed business name published in the source. Historical entries describe that edition, including businesses whose ownership or name later changed.

Published rankingEdition / tierAssessed business
Top 20 Centers of Excellence 20252025 · Tier IIDana-Farber Brigham Cancer Center
Top 20 Centers of Excellence 20242024 · Tier IIDana-Farber Brigham Cancer Center
Top 20 Centers of Excellence 20232023 · Tier IIDana-Farber Brigham Cancer Center

Rankings and recognition

2026

Tier II

Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.

Related Economy analysis

Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:

Sources and data transparency

Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.

  1. Healthcare Ranking — Top 30 Centers of Excellence 2026 — 2026 inclusion and tier classification.
  2. The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
  3. The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
  4. The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.

Corrections and Updates

Factual corrections, updated institutional information, and supporting references may be submitted through The Economy Portal. All proposed changes are subject to editorial verification before publication.

First published: 29 August 2026

Last substantively reviewed: 29 August 2026

Profile scope: Centers of Excellence

This profile has been compiled from publicly available institutional and editorial sources. The profiled organization does not determine its inclusion, editorial characterization or ranking status.

Documented company information

Dana-Farber Cancer Institute and Brigham and Women’s Hospital collaborate to provide adult cancer care; this is a clinical collaboration, not a separate hospital ownership merger. Source.

The adult-cancer collaboration remains active, with specialized multidisciplinary centers. Dana-Farber says the Brigham clinical collaboration will end in September 2028 during transition to a new BIDMC clinical collaboration. Source.